

## **Executive Officer Notice: Funding of Riximyo (rituximab) and Ruxience (rituximab) under the Ontario Drug Benefit Program**

**August 24, 2020**

**Effective July 31, 2020,**

- Riximyo (rituximab) is listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for eligible ODB recipients for the treatment of Rheumatoid Arthritis (RA).
- Ruxience (rituximab) is listed on the ODB Formulary as a LU benefit for eligible ODB recipients for the treatment of RA, and for the treatment and management of patients with Granulomatosis with Polyangiitis [(GPA), also known as Wegener's Granulomatosis (WG)] or microscopic polyangiitis (MPA).

Details of the LU criteria for RA and GPA/MPA have been posted in the July 2020 Formulary update which can be found on the ministry's website at:

[http://www.health.gov.on.ca/en/pro/programs/drugs/edition\\_43.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx)

Riximyo and Ruxience are also funded for specific oncology indications through the Ministry's New Drug Funding Program (NDFP) administered by Ontario Health (Cancer Care Ontario). The funding criteria for Riximyo and Ruxience for oncology indications will be communicated by Ontario Health.

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

### **Additional Information:**

#### **For pharmacies:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

#### **For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.